Deslorelin vs Mod-GRF(1-29)
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Deslorelin
Potent GnRH super agonist approximately 100× more potent than native GnRH. Used in veterinary medicine for estrus suppression and in human medicine for precocious puberty treatment. In research protocols, used for pituitary desensitization to reset the HPG axis or induce controlled medical suppression of sex hormone production.
Full profileMod-GRF(1-29)
Mod-GRF(1-29) is a stabilized analog of growth hormone-releasing hormone (GHRH) that spans residues 1–29 of the native peptide. Unlike CJC-1295 (which includes a Drug Affinity Complex for multi-day half-life), Mod-GRF(1-29) has a short ~30-minute active window — mimicking the natural GHRH pulse pattern. It is the preferred GHRH component for precise, pulsatile GH protocols when combined with a GHRP.
Full profile| Deslorelin | Mod-GRF(1-29) | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | SuvaPryn, Ovuplant, D-His6-Pro9-Et-GnRH | Modified GRF(1-29), CJC-1295 without DAC, Tetrasubstituted GRF, Sermorelin analog |
| Evidence | Research-stage | Research-stage |
| Dosing range | 50mcg–200mcg mcg, Daily SC for continuous suppression; single or short course for pituitary reset | 100mcg–200mcg mcg, 2–3x daily, co-administered with a GHRP (pre-sleep, pre-workout, and/or upon waking) |
| Administration | Subcutaneous implant (veterinary), Subcutaneous injection | Subcutaneous injection, Intramuscular injection |
| Key side effects | Hot flashes, Bone density loss (prolonged suppression), Suppression of testosterone or estrogen, Mood changes, irritability | Water retention (mild, dose-dependent), Tingling / numbness in extremities (carpal tunnel-like at high doses), Increased appetite (via GHRP component — less with Mod-GRF alone), Flushing or warmth at injection site |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: Deslorelin — Subcutaneous implant (veterinary), Subcutaneous injection; Mod-GRF(1-29) — Subcutaneous injection, Intramuscular injection.
- Frequency: Deslorelin is typically Daily SC for continuous suppression; single or short course for pituitary reset; Mod-GRF(1-29) is 2–3x daily, co-administered with a GHRP (pre-sleep, pre-workout, and/or upon waking).
How each works
Deslorelin
Deslorelin produces a robust initial LH/FSH surge (flare effect) followed by profound, sustained pituitary desensitization with continued exposure. This biphasic response is consistent across all high-affinity GnRH super agonists. The flare phase is exploited for reproductive timing in veterinary medicine; the desensitization phase creates the clinical suppression used in precocious puberty and research HPG axis reset protocols.
Mod-GRF(1-29)
Native GHRH(1-29) is rapidly cleaved by plasma dipeptidyl peptidase IV (DPP-IV) within 2–3 minutes. Mod-GRF(1-29) incorporates four amino acid substitutions (positions 2, 8, 15, 27) that resist DPP-IV degradation, extending the half-life to approximately 30 minutes while preserving GHRH receptor binding affinity. This creates a half-life window aligned with physiological GH pulsatility, making it suitable for 2–3x daily injections that mimic natural GH release patterns.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.